EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY-NC-ND 4.0

A prospective study to assess the effectiveness and safety of the BlueWind System in the treatment of patients diagnosed with urgency urinary incontinence

Prospektive Studie zur Wirksamkeit und Sicherheit des BlueWind Systems bei Patientinnen mit Dranginkontinenz

John P F A Heesakkers, Philip Toozs-Hobson, Suzette E Sutherland, Alex Digesu, Cindy L Amundsen, Rebecca J McCrery, Stefan De Wachter iD, Emily R Kean, Frank Martens iD, Kevin Benson, Kimberly L Ferrante, Kevin J Cline und 4 weitere

Neurourology and Urodynamics · 2024-09 · 43 (7) · 1491-1503

DOI: 10.1002/nau.25477 ↗

Auf einen Blick

Bei 151 implantierten Patientinnen mit Dranginkontinenz waren 6 und 12 Monate nach Aktivierung 76,4 % bzw. 78,4 % Responder. Es traten keine schwerwiegenden geräte- oder verfahrensbedingten SAE auf.

Fragestellung

Wie wirksam und sicher ist das BlueWind iTNM-System bei erwachsenen Frauen mit Dranginkontinenz?

Methode

Prospektive, multizentrische, einarmige, offene Pivotal-Studie bei erwachsenen Frauen mit UUI; Beurteilung nach 6 und 12 Monaten.

Ergebnisse

151 Teilnehmerinnen wurden implantiert; 144 und 140 schlossen die 6- bzw. 12-Monats-Visite ab. ITT: 76,4 % und 78,4 % Responder nach 6 bzw. 12 Monaten. Von 139 mit 12-Monats-Tagebuch waren 82 % Responder, 50 % trocken.

Schlussfolgerung der Autor:innen

Die iTNM-Therapie zeigte eine klinisch relevante und statistisch signifikante Verbesserung der UUI-Symptome bei hohem Sicherheitsprofil.

Kernaussagen

  • 76,4 % bzw. 78,4 % Responder nach 6 und 12 Monaten
  • 82 % Responder und 50 % trocken bei 12-Monats-Tagebuch
  • Keine schwerwiegenden geräte- oder verfahrensbedingten SAE

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift Neurourology and Urodynamics, online erschienen am 18.04.2024. Verfasst von John P F A Heesakkers und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Maastricht UMC, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Urinary Incontinence, Urge. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The study was funded by BlueWind Medical Inc..

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Overactive bladder (OAB) affects one in six adults in Europe and the United States and impairs the quality of life of millions of individuals worldwide. When conservative management fails, third‐line treatments including tibial neuromodulation (TNM) is often pursued. TNM has traditionally been accomplished percutaneously in clinic.

Objective

A minimally invasive implantable device activated by a battery‐operated external wearable unit has been developed for the treatment of urgency urinary incontinence (UUI), mitigating the burden of frequent clinic visits and more invasive therapies that are currently commercially available.

Methods

A prospective, multicenter, single‐arm, open‐label, pivotal study evaluated the safety and effectiveness of the device in adult females with UUI (i.e., wet OAB) (BlueWind Implantable Tibial Neuromodulation [iTNM] system; IDE number #G200013; NCT03596671). Results with the device were previously published under the name RENOVA iStim, which has been since renamed as the Revi™ System. Approximately 1‐month post‐implantation of the device, participants delivered therapy at their convenience and completed a 7‐day voiding diary before visits 6‐ and 12‐months post‐treatment initiation. The primary efficacy and safety endpoints were the proportion of responders to therapy ( ≥ 50% improvement on average number of urgency‐related incontinence episodes) and incidence of adverse events from implantation to 12‐month post‐activation.

Results

A total of 151 participants, mean age 58.8 (SD: 12.5), were implanted; 144 and 140 completed the 6‐ and 12‐month visits, respectively. The participants demonstrated mean baseline of 4.8 UUI/day (SD 2.9) and 10 voids/day (SD 3.3). Six and 12‐months post‐activation, 76.4% and 78.4% of participants, respectively, were responders to therapy in an intent‐to‐treat analysis. Of the 139 participants with completed 12‐month diaries, 82% were responders, 50% were classified as “dry” (on at least 3 consecutive diary days), and 93.5% of participants reported that their symptoms improved. No implanted participant experienced an SAE related to the procedure or device. Conclusions iTNM, delivered and powered by a patient‐controlled external wearable communicating with an implant, demonstrated clinically meaningful and statistically significant improvement in UUI symptoms and a high safety profile. This therapy highlights the value of patient‐centric therapy for the treatment of UUI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Incontinence, UrgeHumansFemaleMiddle AgedProspective StudiesAgedTreatment OutcomeElectric Stimulation TherapyAdultImplantable NeurostimulatorsUrinary Bladder, OveractiveTibial Nerve

Stichwörter der Autor:innen

neuromodulationoveractive bladderpatient centric therapytibial implantable neuromodulationurgency urinary incontinence

Autor:innen und Institutionen

  • Department of Urology, Maastricht UMC, Maastricht, The Netherlands.
  • Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
  • Department of Urology, UW Medicine Pelvic Health Center, University of Washington, Seattle, Washington, USA.
  • St Mary's Hospital, Imperial College NHS Trust, London, UK.
  • Department of Obstetrics and Gynecology, Division of Urogynecology and Reconstructive Pelvic Surgery, Duke University, Durham, North Carolina, USA.
  • Adult Pediatric Urology & Urogynecology, Omaha, Nebraska, USA.

ORCID-Profile: Stefan De Wachter, Frank Martens

Förderung

  • The study was funded by BlueWind Medical Inc.

Zitieren

APA

Heesakkers, J. P. F. A., Toozs-Hobson, P., Sutherland, S. E., Digesu, A., Amundsen, C. L., McCrery, R. J., De Wachter, S., Kean, E. R., Martens, F., Benson, K., Ferrante, K. L., Cline, K. J., Padron, O. F., Giusto, L., Lane, F. L., & Dmochowski, R. R. (2024). A prospective study to assess the effectiveness and safety of the BlueWind System in the treatment of patients diagnosed with urgency urinary incontinence. Neurourology and Urodynamics, 43(7), 1491-1503. https://doi.org/10.1002/nau.25477

Vancouver

Heesakkers JPFA, Toozs-Hobson P, Sutherland SE, Digesu A, Amundsen CL, McCrery RJ, et al. A prospective study to assess the effectiveness and safety of the BlueWind System in the treatment of patients diagnosed with urgency urinary incontinence. Neurourology and Urodynamics. 2024;43(7):1491-1503. doi:10.1002/nau.25477

BibTeX
@article{Heesakkers2024,
  author = {Heesakkers, John P F A and Toozs-Hobson, Philip and Sutherland, Suzette E and Digesu, Alex and Amundsen, Cindy L and McCrery, Rebecca J and De Wachter, Stefan and Kean, Emily R and Martens, Frank and Benson, Kevin and Ferrante, Kimberly L and Cline, Kevin J and Padron, Osvaldo F and Giusto, Laura and Lane, Felicia L and Dmochowski, Roger R},
  title = {A prospective study to assess the effectiveness and safety of the BlueWind System in the treatment of patients diagnosed with urgency urinary incontinence},
  journal = {Neurourology and Urodynamics},
  year = {2024},
  volume = {43},
  number = {7},
  pages = {1491--1503},
  doi = {10.1002/nau.25477}
}
Kostenlos starten →